Literature DB >> 23673188

Vascular endothelial growth factor gene (VEGFA) polymorphisms may serve as prognostic factors for recurrent depressive disorder development.

Piotr Gałecki1, Elżbieta Gałecka, Michael Maes, Agata Orzechowska, Dominika Berent, Monika Talarowska, Kinga Bobińska, Andrzej Lewiński, Małgorzata Bieńkiewicz, Janusz Szemraj.   

Abstract

Recurrent depressive disorder (rDD) is a multifactorial disease. Vascular endothelial growth factor (VEGF) is one of the factors that have been suggested to play a role in the etiology and/or development of this disease. Limited information related to the role of VEGFA gene polymorphism in depressive disorder is available. The aim of the study was to analyze the association between VEGFA gene polymorphisms (+405G/C; rs2010963, +936C/T; rs 3025039), VEGFA gene expression, and its serum protein levels in rDD in the Caucasian population. In the current study, 268 patients and 200 healthy controls of the Caucasian origin were involved. Genotyping and gene expression were performed using polymerase chain reaction (PCR)-based methods. Enzyme-linked immunosorbent assay (ELISA) was used for detection of circulating serum VEGF levels. The distribution of VEGFA polymorphism +405G/C differed significantly between rDD patients and healthy subjects. The results of this study indicated that the C allele and CC genotype of VEGFA are risk factors for rDD. Haplotypes CC and TG are the important factors for depression development. Further, VEGFA mRNA expression and VEGF levels were higher in rDD patients than in controls. The VEGFA gene polymorphism may serve as a prognostic factor for rDD development. Our study showed higher levels of both VEGFA mRNA in the peripheral blood cells and serum VEGF in patients diagnosed with rDD than in healthy controls. The obtained results suggest VEGF and the gene encoding the molecule play a role in the etiology of the disease and should be further investigated.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ACTB; Beta-2-microglobulin gene; CI; CIDI; COX-2; Caucasian population; Composite International Diagnostic Interview; ELISA; GADPH; Glyceraldehyde-3- phosphate dehydrogenase gene; HDRS; Hamilton Depression Rating Scale; Haplotypes; LD; M2B; MPO; ORdis; PCR-RFLP; Peripheral blood; RPL1(3)A; Recurrent depressive disorder; Ribosomal protein L13a gene; SD; TMB; VEGF; VEGF levels inflammation; VEGFA; VEGFA gene; Vascular Endothelial Growth Factor gene; Vascular endothelial growth factor; WHO; World Health Organization; beta actin gene; confidence interval; cycloooxygenase-2; disease odds ratio; enzyme – linked immunosorbent assay; iNOS; inducible nitric oxide synthase; linkage disequilibrium; myeloperoxidase; polymerase chain reaction/restriction fragment length polymorphism; qRT-PCR; quantitative real-time polymerase chain reaction; rDD; recurrent depressive disorder; standard deviations; tetramethylbenzidine

Mesh:

Substances:

Year:  2013        PMID: 23673188     DOI: 10.1016/j.pnpbp.2013.04.011

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  9 in total

Review 1.  Role of trophic factors GDNF, IGF-1 and VEGF in major depressive disorder: A comprehensive review of human studies.

Authors:  Ajaykumar N Sharma; Bruno Fernando Borges da Costa e Silva; Jair C Soares; André F Carvalho; Joao Quevedo
Journal:  J Affect Disord       Date:  2016-03-02       Impact factor: 4.839

Review 2.  A Systematic Review of Candidate Genes for Major Depression.

Authors:  Audrone Norkeviciene; Romena Gocentiene; Agne Sestokaite; Rasa Sabaliauskaite; Daiva Dabkeviciene; Sonata Jarmalaite; Giedre Bulotiene
Journal:  Medicina (Kaunas)       Date:  2022-02-14       Impact factor: 2.430

3.  VEGFA rSNPs, transcriptional factor binding sites and human disease.

Authors:  Norman E Buroker
Journal:  J Physiol Sci       Date:  2013-10-06       Impact factor: 2.781

4.  Vascular endothelial growth factor plasma levels in depression and following electroconvulsive therapy.

Authors:  Karen M Ryan; Declan M McLoughlin
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-07-02       Impact factor: 5.270

5.  Proteasome system dysregulation and treatment resistance mechanisms in major depressive disorder.

Authors:  A Minelli; C Magri; A Barbon; C Bonvicini; M Segala; C Congiu; S Bignotti; E Milanesi; L Trabucchi; N Cattane; M Bortolomasi; M Gennarelli
Journal:  Transl Psychiatry       Date:  2015-12-01       Impact factor: 6.222

6.  Inflammation and vascular remodeling in the ventral hippocampus contributes to vulnerability to stress.

Authors:  J Pearson-Leary; D Eacret; R Chen; H Takano; B Nicholas; S Bhatnagar
Journal:  Transl Psychiatry       Date:  2017-06-27       Impact factor: 6.222

7.  Screening and Identification of Antidepressant Active Ingredients from Puerariae Radix Extract and Study on Its Mechanism.

Authors:  Guoze Wang; Peng Luo; Shuai Zhang; Qun Huang; Shuling Zhang; Qibing Zeng; Jingxin Mao
Journal:  Oxid Med Cell Longev       Date:  2021-09-09       Impact factor: 6.543

8.  Serum MicroRNAs as Potential Biomarkers of AMD.

Authors:  Maciej Szemraj; Anna Bielecka-Kowalska; Katarzyna Oszajca; Marta Krajewska; Roman Goś; Piotr Jurowski; Michał Kowalski; Janusz Szemraj
Journal:  Med Sci Monit       Date:  2015-09-14

9.  Epistatic Interaction Between 5-HT1A and Vascular Endothelial Growth Factor Gene Polymorphisms in the Northern Chinese Han Population With Major Depressive Disorder.

Authors:  Dong Han; Zhengxue Qiao; Dong Qi; Jiarun Yang; Xiuxian Yang; Jingsong Ma; Lin Wang; Xuejia Song; Erying Zhao; Jian Zhang; Yanjie Yang; Xiaohui Qiu
Journal:  Front Psychiatry       Date:  2019-04-16       Impact factor: 4.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.